Dako held a meeting for the biological IPO: the annual revenue was 837million, and Wu Qingjun and his daughter were the actual controllers

RedI network Lei Jianping 7 month 25 Reported Wednesday

Shenzhen dakowei Biotechnology Co., Ltd （ abbreviation ：“ Dako is a creature ”） recently IPO Past meeting , The next step is to submit the registration , Prepare to be listed on the growth enterprise market of Shenzhen Stock Exchange .

Dako raised money for the biological project 8 Billion , among ,1.27 Billion yuan is used for the construction project of biological reagent production center of Shenzhen dakowei Biological Engineering Co., Ltd ,9350 Ten thousand yuan for Dako is （ Shenzhen ） Medical equipment manufacturing center construction project of medical equipment Co., Ltd ,2.82 Billion yuan is used for the R & D center construction project of Shenzhen dakowei Biotechnology Co., Ltd ,1.98 Billion yuan is used for the construction project of marketing service network and informatization upgrading ,1 Billion yuan is used to supplement working capital projects .

Annual revenue 8.37 Billion

Dakowei biology is a professional provider focusing on the field of life science research services and pathological diagnosis . In the field of life science research services , The company is mainly engaged in the agent sales of scientific research reagents and instruments , And the independent research and development of some scientific research reagents 、 Production and sales ; In the field of pathological diagnosis , The company is mainly engaged in the research and development of pathological diagnosis equipment and reagents 、 Production and sales .

The prospectus shows , Dako is a creature 2019 year 、2020 year 、2021 The annual revenue is 4.35 One hundred million yuan 、6.05 One hundred million yuan 、8.37 One hundred million yuan ; The net profit is respectively 1382.96 Ten thousand yuan 、8133.45 Ten thousand yuan 、1.04 One hundred million yuan ; The net profit after deducting non profits is 1186.66 Ten thousand yuan 、7547.65 Ten thousand yuan 、9774.2 Ten thousand yuan .

The R & D expenditure of the company during the reporting period was 2425.41 Ten thousand yuan 、2172.25 Million and $ 3296.72 Ten thousand yuan , The proportion of business income is 5.57%、3.59% and 3.94%.、

During the reporting period , The company provides scientific research Reagent Suppliers BioLegend The purchase amounts of are 1.36 One hundred million yuan 、1.68 Million dollars 2.48 One hundred million yuan , The proportion in the total procurement of each period in the reporting period is 49.19%、44.90% and 51.43%, The company has the risk of a high proportion of procurement from a single supplier .

BioLegend Committed to providing first-class services in the field of biomedical research 、 High quality flow cytometry antibodies and corresponding kits and other products , It is one of the major international flow cytometry antibody manufacturers .

The company with BioLegend since 2008 Cooperation began in , Sell as an exclusive agent BioLegend Flow cytometry antibody related reagents , Mutual benefit and win-win results have been formed 、 Long term and stable cooperative relationship .

A company listed on the New York Stock Exchange PerkinElmer（ Stock code ：PKI） On 2021 year 7 month 26 Announced its intention to acquire BioLegend All equity , This transaction was made on 2021 year 9 Month to complete . Upon completion of the above transaction , The company with BioLegend Continue to maintain the exclusive agency relationship .

Wuqingjun and his daughter are the actual controllers

Since the establishment of the joint stock company , Dako is the actual controller of biology, Wu Qingjun and Ms. Wu Yingjie , No changes have occurred .

IPO front , Wu Qingjun directly owns the company 11.4028% equity ; meanwhile , Wu Qingjun controls the company through Kunpeng Juxian 15.1519% Equity of , And served as the chairman of the company 、 Position of general manager .

Wu Yingjie directly owns the company 15.4550% equity , Wu Yingjie is the daughter of Wu Qingjun .

Wu Qingjun and Ms. Wu Yingjie jointly control the company through direct and indirect means 42.0097% Shares of , The two are the actual controllers of the company .

Hejunfeng holds 12.8792%, He Zhenglong （ Guardian ： He Junfeng ） The shareholding is 7.7275%, Tibet Junfeng holds 7.4741%, Zhang Li holds 4.0522%, Guiyang Zhongtian 、 Shenzhen anzhuoxin 、 Guangdong songchuang holds 3.1607%, Lin Chuanyong 、 Li Jie 、 Tian Zengsui holds shares of 3.0186%;

Shenzhen Jiahui holds 2.1072%, Li Haoyuan holds 1.4588%, Shenzhen hi tech Investment Co., Ltd （SS） The shareholding is 1.0143%, Wang Xia holds 0.9725%, Wen Lijie 、 Zong Jinchun holds 0.8104%, Chen Xu holds 0.2536%.

IPO after , Wu Yingjie holds 11.5913%, Kunpeng Juxian holds 11.3641%, Hejunfeng holds 9.6594%, Wuqingjun holds 8.5521%, He Zhenglong （ Guardian ： He Junfeng ） The shareholding is 5.7956%, Tibet Junfeng holds 5.6056%, Zhang Li holds 3.0392%.

———————————————

Lei Di was founded by Lei Jianping, a senior media person , If reproduced, please indicate the source .